

**In the Claims:**

Please cancel claims 31-42 without prejudice or disclaimer of the subject matter contained therein and amend the claims as follows:

✓  
C1  
43. (Twice Amended) The isolated polynucleotide of claim 18 [39] encoding a fusion polypeptide, wherein the first polynucleotide sequence encodes part of the fusion polypeptide.

**REMARKS**

This Amendment is responsive to the Office Action mailed May 31, 2000 (Paper No. 11). Entry of this Amendment and reconsideration of the subject application in view thereof are respectfully requested.

**Claims**

Claims 18-43 were pending. Claims 18-30 and 43 stand allowed. Claims 31-42 stood rejected.

Claims 31-42 have been canceled without prejudice or disclaimer of the subject matter therein. Moreover, Applicants reserve the right to prosecute, in one or more patent applications, the canceled claims, the claims to non-elected inventions, the claims as originally filed, and any other claims supported by the specification.

Claim 43 has been amended to more particularly and distinctly define the invention.

**Support**

Support for the amendments to the claims is apparent. No new matter is added.

**Claim Rejections under 35 U.S.C. § 112, First Paragraph**

Claims 31-42 stood rejected under 35 U.S.C. § 112, first paragraph, as non-enabled. Specifically, the Examiner asserts that

[t]he instant application does not disclose a full open reading frame (ORF) for SEQ ID NO:3, which SEQ ID NO: encodes SEQ ID NO:4. The region of SEQ ID NO:3 that encodes SEQ ID NO:4 is